— Know what they know.
Not Investment Advice
Also trades as: 0QF.F (FSX) · $vol 0M

MRNA NASDAQ

Moderna, Inc.
1W: -5.5% 1M: -15.0% 3M: -5.2% YTD: +12.7% 1Y: +76.3% 3Y: -69.6% 5Y: -66.5%
$46.88
-0.38 (-0.80%)
 
Weekly Expected Move ±9.0%
$40 $45 $49 $53 $58
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 27 · $18.6B mcap · 370M float · 2.09% daily turnover · Short 58% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
29.1 / 100
NoneWeakNarrowWide
Primary source: Cost Advantage  ·  ROIC: -56.5%  ·  5Y Avg: 4.0%
Cost Advantage ★
42
Intangibles
22
Switching Cost
27
Network Effect
27
Scale
29
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. MRNA has No discernible competitive edge (29.1/100). The business operates without significant structural advantages. The primary source of advantage is Cost Advantage. Negative ROIC of -56.5% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$33
Low
$41
Avg Target
$49
High
Based on 4 analysts since May 1, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 7Hold: 16Sell: 4Strong Sell: 0
Rating Summary
ConsensusHold
Avg Target$40.40
Analysts5
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-04 UBS $36 $45 +9 -5.2% $47.47
2026-05-04 RBC Capital Luca Issi $30 $38 +8 -18.9% $46.87
2026-05-01 Goldman Sachs Initiated $49 +8.0% $45.37
2026-05-01 Morgan Stanley $30 $33 +3 -25.3% $44.18
2026-03-03 Jefferies Andrew Tsai $30 $37 +7 -25.7% $49.83
2026-02-17 RBC Capital Luca Issi $25 $30 +5 -29.5% $42.54
2026-02-17 Evercore ISI Cory Kasimov $105 $35 -70 -19.0% $43.19
2026-02-17 Bernstein $55 $45 -10 +6.6% $42.23
2026-02-16 UBS $34 $36 +2 -14.8% $42.23
2026-02-16 Morgan Stanley $28 $30 +2 -29.0% $42.23
2026-01-06 UBS $18 $34 +16 -4.7% $35.66
2025-12-12 Morgan Stanley $94 $28 -66 -6.4% $29.90
2025-12-11 Jefferies $55 $30 -25 +1.3% $29.62
2025-11-21 RBC Capital Luca Issi $75 $25 -50 +8.2% $23.10
2025-11-21 UBS $40 $18 -22 -19.5% $22.36
2025-11-21 Piper Sandler $69 $63 -6 +181.8% $22.36
2025-11-20 Wolfe Research $304 $17 -287 -24.0% $22.36
2025-11-17 Berenberg Bank Initiated $28 +13.0% $24.77
2025-10-23 UBS $151 $40 -111 +49.0% $26.85
2025-08-22 Leerink Partners $102 $15 -87 -44.7% $27.12
2025-08-01 Citigroup Geoff Meacham Initiated $40 +35.3% $29.56
2025-02-14 J.P. Morgan Jessica Fye $165 $45 -120 +41.0% $31.92
2024-11-18 Piper Sandler Edward Tenthoff $115 $69 -46 +85.1% $37.27
2024-11-18 HSBC Yifeng Liu $82 $58 -24 -31.7% $84.93
2024-10-17 Bernstein Courtney Breen Initiated $55 -4.3% $57.46
2024-10-14 Jefferies Michael Yee $65 $55 -10 -4.7% $57.73
2024-09-13 Piper Sandler Edward Tenthoff $157 $115 -42 +65.0% $69.68
2024-09-13 RBC Capital Luca Issi $90 $75 -15 +7.6% $69.68
2024-09-13 Loop Capital Markets Leah Rush Cann $310 $238 -72 +241.6% $69.68
2024-09-12 Jefferies Michael Yee $120 $65 -55 -6.7% $69.68
2024-09-12 Evercore ISI Cory Kasimov $120 $105 -15 +55.1% $67.68
2024-09-12 Morgan Stanley Matthew Harrison $95 $94 -1 +39.2% $67.51
2024-09-12 Jefferies Michael Yee $180 $120 -60 +77.7% $67.52
2024-08-28 Robert W. Baird Peter Arment Initiated $220 +180.2% $78.52
2024-08-28 HSBC Yifeng Liu Initiated $82 +3.8% $78.98
2024-08-06 Deutsche Bank Emmanuel Papadakis $85 $80 -5 -2.8% $82.30
2024-08-05 RBC Capital Luca Issi $160 $90 -70 +4.0% $86.58
2024-08-02 Piper Sandler Edward Tenthoff $217 $157 -60 +74.4% $90.03
2024-06-12 Oppenheimer Hartaj Singh $163 $179 +16 +20.6% $148.39
2024-06-10 Loop Capital Markets Leah Rush Cann Initiated $310 +110.2% $147.47
2024-06-07 Jefferies Michael Yee $155 $180 +25 +18.4% $152.03
2024-05-31 RBC Capital Luca Issi $135 $160 +25 +12.8% $141.83
2024-05-13 Evercore ISI Cory Kasimov Initiated $120 -4.5% $125.67
2024-05-09 Deutsche Bank Emmanuel Papadakis $155 $85 -70 -31.5% $124.06
2024-05-07 UBS Eliana Merle $143 $151 +8 +23.6% $122.13
2024-05-03 Jefferies Michael Yee $125 $155 +30 +26.0% $123.02
2024-05-03 Canaccord Genuity Bill Maughan Initiated $106 -15.6% $125.59
2024-05-03 Oppenheimer Hartaj Singh $142 $163 +21 +29.8% $125.59
2024-05-03 RBC Capital Luca Issi Initiated $135 +7.5% $125.59
2024-05-02 Morgan Stanley Matthew Harrison $89 $95 +6 -24.0% $125.00

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C-
May 22, 2026
DCF
1
ROE
1
ROA
1
D/E
2
P/E
1
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. MRNA receives an overall rating of C-. Areas of concern: DCF (1/5), ROE (1/5), ROA (1/5), D/E (2/5), P/E (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-05-01 C C-
2026-04-24 C- C
2026-04-01 C C-
2026-02-17 C+ C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

31 Grade D
Profitability
0
Balance Sheet
0
Earnings Quality
48
Growth
33
Value
39
Momentum
38
Safety
90
Cash Flow
30
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. MRNA scores highest in Safety (90/100) and lowest in Profitability (0/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
3.85
Safe Zone
Piotroski F-Score
1/9
Beneish M-Score
-2.10
Unlikely Manipulator
Ohlson O-Score
-7.88
Bankruptcy prob: 0.0%
Low Risk
Credit Rating
BBB
Score: 59.6/100
Trend: Improving
Earnings Quality
OCF/NI: 0.45x
Accruals: -13.2%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. MRNA scores 3.85, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. MRNA scores 1/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. MRNA's score of -2.10 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. MRNA's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. MRNA receives an estimated rating of BBB (score: 59.6/100), with a improving trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-5.80x
PEG
-2.89x
P/S
8.37x
P/B
2.50x
P/FCF
-12.68x
P/OCF
EV/EBITDA
-5.47x
EV/Revenue
7.27x
EV/EBIT
-5.07x
EV/FCF
-10.23x
Earnings Yield
-15.92%
FCF Yield
-7.88%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. MRNA currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.018
NI / EBT
×
Interest Burden
0.983
EBT / EBIT
×
EBIT Margin
-1.434
EBIT / Rev
×
Asset Turnover
0.168
Rev / Assets
×
Equity Multiplier
1.354
Assets / Equity
=
ROE
-32.7%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. MRNA's ROE of -32.7% is driven by Asset Turnover (0.168), indicating efficient use of assets to generate revenue. A tax burden ratio of 1.02 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$46.88
Median 1Y
$40.74
5th Pctile
$12.72
95th Pctile
$132.35
Ann. Volatility
72.2%
Analyst Target
$40.40
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Stéphane Bancel
Chief Executive Officer
$1,677,739 $6,897,455 $19,932,217
Stephen Hoge, M.D.
President
$1,260,000 $9,196,606 $18,054,133
James Mock Financial
ancial Officer
$852,192 $2,452,404 $5,857,761
Shannon Thyme Klinger
Chief Legal Officer and Corporate Secretary
$852,192 $2,145,838 $5,397,914

CEO Pay Ratio

92:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $19,932,217
Avg Employee Cost (SGA/emp): $216,596
Employees: 4,700

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
4,700
-19.0% YoY
Revenue / Employee
$413,617
Rev: $1,944,000,000
Profit / Employee
$-600,426
NI: $-2,822,000,000
SGA / Employee
$216,596
Avg labor cost proxy
R&D / Employee
$666,383
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE 1.9% 3.8% 1.5% 1.8% 1.7% 1.4% 50.3% 28.8% 7.3% -20.8% -28.6% -36.2% -35.6% -13.5% -28.8% -27.1% -23.5% -25.2% -28.9% -32.7% -32.67%
ROA 78.3% 1.6% 76.2% 91.5% 87.8% 73.5% 33.1% 18.9% 4.8% -13.7% -21.3% -27.0% -26.5% -10.0% -21.9% -20.6% -17.8% -19.1% -21.3% -24.1% -24.12%
ROIC -1.9% -3.9% 2.8% 3.4% 3.2% 2.7% 78.9% 44.0% 7.3% -20.2% -51.6% -62.5% -56.4% -32.8% -67.4% -63.7% -55.9% -59.2% -50.9% -56.5% -56.54%
ROCE 1.3% 2.6% 85.6% 1.0% 1.0% 85.9% 45.9% 24.2% 4.1% -11.1% -25.3% -30.9% -27.9% -15.1% -30.0% -28.4% -24.6% -26.3% -26.7% -30.8% -30.83%
Gross Margin 82.2% 85.0% 86.3% 82.9% 69.8% 65.8% 62.8% 56.9% -1.1% -22.4% 67.0% 42.5% 48.0% 72.3% 22.7% 15.9% 16.2% 0.8% 33.3% -1.5% -1.46%
Operating Margin 72.6% 73.7% 77.9% 71.2% 53.6% 36.2% 30.7% -19.9% -5.4% -1.1% 0.2% -7.6% -6.2% -3.8% -1.3% -9.8% -6.4% -25.6% -1.3% -3.6% -3.57%
Net Margin 66.0% 69.0% 70.1% 61.6% 48.1% 32.4% 28.5% 4.3% -4.0% -2.0% 7.7% -7.0% -5.8% 0.7% -1.2% -9.1% -5.8% -19.7% -1.2% -3.5% -3.45%
EBITDA Margin 74.4% 75.1% 79.0% 72.5% 56.0% 41.6% 33.9% -11.9% -4.8% -92.8% 9.9% -6.7% -5.6% 4.3% -1.2% -8.6% -5.4% -13.3% -1.1% -3.4% -3.42%
FCF Margin 1.4% 1.0% 75.2% 59.4% 41.4% 30.0% 24.3% 4.1% -7.1% -29.0% -56.0% -71.2% -79.1% -78.2% -1.3% -1.3% -1.1% -1.2% -1.1% -71.1% -71.10%
OCF Margin 1.4% 1.0% 76.8% 61.1% 43.3% 32.1% 26.4% 6.7% -2.1% -22.7% -45.7% -55.9% -64.4% -63.4% -93.9% -97.2% -88.1% -89.1% -95.3% -64.9% -64.94%
ROE 3Y Avg snapshot only -36.93%
ROE 5Y Avg snapshot only 3.54%
ROA 3Y Avg snapshot only -27.34%
ROIC 3Y Avg snapshot only -52.91%
ROIC Economic snapshot only -25.62%
Cash ROA snapshot only -11.71%
Cash ROIC snapshot only -30.31%
CROIC snapshot only -33.19%
NOPAT Margin snapshot only -1.21%
Pretax Margin snapshot only -1.41%
R&D / Revenue snapshot only 1.31%
SGA / Revenue snapshot only 44.00%
SBC / Revenue snapshot only 10.52%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio 28.98 23.65 8.97 5.01 4.26 4.14 8.70 13.00 38.35 -11.35 -8.33 -6.82 -7.77 -11.99 -4.50 -3.26 -3.69 -3.23 -4.10 -6.28 -5.801
P/S Ratio 15.15 14.71 6.17 3.35 2.69 2.36 3.85 4.21 4.39 4.30 5.75 7.90 9.06 5.27 5.00 3.49 3.50 4.54 5.95 9.02 8.365
P/B Ratio 39.55 65.22 7.74 5.19 4.23 3.44 3.80 3.25 2.42 2.06 2.84 2.94 3.29 1.92 1.47 1.00 0.98 0.92 1.34 2.32 2.501
P/FCF 11.15 14.67 8.21 5.63 6.50 7.86 15.88 101.63 -61.39 -14.81 -10.27 -11.09 -11.46 -6.74 -3.95 -2.71 -3.06 -3.78 -5.63 -12.68 -12.684
P/OCF 11.02 14.43 8.04 5.47 6.20 7.35 14.60 62.64
EV/EBITDA 24.63 20.90 7.37 3.84 3.13 2.84 6.44 9.87 30.84 -16.86 -9.72 -7.96 -10.13 -9.66 -2.87 -1.46 -1.63 -1.29 -3.01 -5.47 -5.475
EV/Revenue 14.49 14.32 5.62 2.90 2.25 1.88 3.39 3.62 3.56 3.35 4.68 6.47 7.60 3.82 3.04 1.49 1.45 1.71 3.95 7.27 7.273
EV/EBIT 25.28 21.35 7.49 3.91 3.19 2.91 6.67 10.55 43.81 -13.24 -8.18 -6.99 -8.88 -8.29 -2.72 -1.38 -1.51 -1.21 -2.78 -5.07 -5.071
EV/FCF 10.67 14.28 7.47 4.88 5.43 6.27 13.98 87.41 -49.85 -11.54 -8.35 -9.08 -9.61 -4.88 -2.40 -1.16 -1.26 -1.43 -3.74 -10.23 -10.229
Earnings Yield 3.5% 4.2% 11.1% 19.9% 23.5% 24.1% 11.5% 7.7% 2.6% -8.8% -12.0% -14.7% -12.9% -8.3% -22.2% -30.7% -27.1% -30.9% -24.4% -15.9% -15.92%
FCF Yield 9.0% 6.8% 12.2% 17.8% 15.4% 12.7% 6.3% 1.0% -1.6% -6.8% -9.7% -9.0% -8.7% -14.8% -25.3% -36.9% -32.7% -26.4% -17.8% -7.9% -7.88%
Price/Tangible Book snapshot only 2.320
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 1.43 1.43 1.76 1.76 1.76 1.76 2.73 2.73 2.73 2.73 3.42 3.42 3.42 3.42 3.67 3.67 3.67 3.67 3.29 3.29 3.293
Quick Ratio 1.42 1.42 1.60 1.60 1.60 1.60 2.54 2.54 2.54 2.54 3.36 3.36 3.36 3.36 3.62 3.62 3.62 3.62 3.22 3.22 3.216
Debt/Equity 0.09 0.09 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.09 0.09 0.09 0.09 0.07 0.07 0.07 0.07 0.22 0.22 0.222
Net Debt/Equity -1.71 -1.71 -0.69 -0.69 -0.69 -0.69 -0.46 -0.46 -0.46 -0.46 -0.53 -0.53 -0.53 -0.53 -0.58 -0.58 -0.58 -0.58 -0.45 -0.45 -0.449
Debt/Assets 0.03 0.03 0.04 0.04 0.04 0.04 0.05 0.05 0.05 0.05 0.07 0.07 0.07 0.07 0.05 0.05 0.05 0.05 0.16 0.16 0.155
Debt/EBITDA 0.06 0.03 0.07 0.06 0.06 0.07 0.12 0.22 0.98 -0.66 -0.38 -0.30 -0.33 -0.62 -0.22 -0.23 -0.27 -0.25 -0.75 -0.65 -0.648
Net Debt/EBITDA -1.11 -0.56 -0.73 -0.59 -0.61 -0.72 -0.88 -1.61 -7.14 4.79 2.24 1.76 1.95 3.68 1.85 1.96 2.31 2.14 1.52 1.31 1.314
Interest Coverage 267.30 491.33 739.06 775.00 746.95 534.20 331.17 158.53 21.45 -55.12 -102.74 -136.20 -153.71 -97.04 -149.29 -178.26 -209.36 -393.12 -1383.00 -177.28 -177.278
Equity Multiplier 2.86 2.86 1.74 1.74 1.74 1.74 1.35 1.35 1.35 1.35 1.33 1.33 1.33 1.33 1.30 1.30 1.30 1.30 1.43 1.43 1.426
Cash Ratio snapshot only 2.918
Debt Service Coverage snapshot only -164.222
Cash to Debt snapshot only 3.027
FCF to Debt snapshot only -0.826
Defensive Interval snapshot only 703.8 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 1.50 2.54 1.11 1.37 1.39 1.29 0.75 0.58 0.42 0.36 0.31 0.23 0.23 0.23 0.20 0.19 0.19 0.14 0.15 0.17 0.168
Inventory Turnover 41.15 71.52 3.52 4.62 5.47 5.98 4.53 4.34 3.80 4.75 8.15 6.95 5.87 2.87 9.18 9.14 9.17 12.26 12.36 18.77 18.770
Receivables Turnover 9.58 16.27 7.77 9.61 9.76 9.06 8.28 6.48 4.63 4.02 6.00 4.53 4.42 4.44 5.12 5.02 4.90 3.55 7.17 8.21 8.210
Payables Turnover 77.09 133.97 16.36 21.51 25.45 27.81 13.73 13.16 11.51 14.40 9.32 7.94 6.71 3.29 3.17 3.15 3.16 4.23 4.62 7.02 7.019
DSO 38 22 47 38 37 40 44 56 79 91 61 81 83 82 71 73 75 103 51 44 44.5 days
DIO 9 5 104 79 67 61 81 84 96 77 45 53 62 127 40 40 40 30 30 19 19.4 days
DPO 5 3 22 17 14 13 27 28 32 25 39 46 54 111 115 116 115 86 79 52 52.0 days
Cash Conversion Cycle 42 25 128 100 90 88 98 113 143 142 66 87 90 98 -4 -3 -1 46 1 12 11.9 days
Fixed Asset Turnover snapshot only 0.780
Operating Cycle snapshot only 63.9 days
Cash Velocity snapshot only 0.384
Capital Intensity snapshot only 5.545
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 62.2% 45.0% 21.1% 7.6% 2.3% 82.0% 6.4% -32.6% -52.7% -55.7% -63.8% -65.1% -52.3% -44.8% -53.1% -39.1% -39.2% -56.1% -39.3% -29.1% -29.12%
Net Income 8.2% 12.8% 17.3% 23.5% 3.0% 66.6% -31.5% -67.3% -91.4% -1.3% -1.6% -2.2% -5.9% 35.8% 24.5% 43.8% 50.5% -40.1% 20.8% 4.9% 4.86%
EPS 7.3% 11.7% 16.0% 23.7% 3.1% 75.5% -27.1% -65.6% -90.6% -1.3% -1.6% -2.3% -5.8% 38.7% 22.5% 44.3% 51.0% -43.3% 22.2% 7.0% 7.02%
FCF 25.5% 17.5% 5.8% 1.6% 1.4% -45.5% -65.6% -95.3% -1.1% -1.4% -1.8% -7.0% -4.3% -48.9% -6.0% -9.9% 12.0% 32.7% 49.3% 60.8% 60.78%
EBITDA 9.7% 15.0% 20.2% 23.0% 3.1% 75.9% -26.5% -67.3% -92.4% -1.1% -1.3% -1.8% -4.1% -9.9% -3.3% 23.7% 27.9% -47.0% 24.8% 7.5% 7.48%
Op. Income 8.4% 13.3% 18.4% 24.7% 3.1% 74.1% -29.2% -70.3% -96.7% -1.2% -1.4% -2.1% -10.0% -1.1% 6.9% 27.4% 29.4% -28.6% 22.1% 8.5% 8.50%
OCF Growth snapshot only 52.65%
Asset Growth snapshot only -12.76%
Equity Growth snapshot only -20.65%
Debt Growth snapshot only 1.56%
Shares Change snapshot only 2.33%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y 6.9% 6.5% 6.0% 5.3% 5.8% 5.5% 3.6% 2.3% 1.0% 26.6% -9.0% -23.6% -43.5% -47.7% -48.4% -52.5% -53.1% -46.8% -46.79%
Revenue 5Y 1.9% 1.5% 1.4% 1.3% 1.2% 1.3% 96.0% 55.2% 19.3% -2.6% -2.60%
EPS 3Y
EPS 5Y
Net Income 3Y
Net Income 5Y
EBITDA 3Y
EBITDA 5Y
Gross Profit 3Y 7.1% 7.0% 6.5% 5.8% 6.7% 6.6% 3.3% 1.5% 40.8% -20.6% -33.9% -29.4% -51.4% -55.0% -55.6% -74.6% -72.7%
Gross Profit 5Y 1.4% 99.4% 1.1% 1.3% 1.3% 1.4% 84.6% 4.3% -18.5%
Op. Income 3Y
Op. Income 5Y
FCF 3Y
FCF 5Y
OCF 3Y
OCF 5Y
Assets 3Y 1.3% 1.3% 1.3% 1.3% 1.5% 1.5% 1.5% 1.5% 35.9% 35.9% 35.9% 35.9% -16.9% -16.9% -16.9% -16.9% -21.9% -21.9% -21.86%
Assets 5Y 56.5% 56.5% 56.5% 56.5% 54.8% 54.8% 54.8% 54.8% 11.0% 11.0% 10.95%
Equity 3Y 1.1% 1.1% 1.1% 1.1% 1.5% 1.5% 1.5% 1.5% 75.5% 75.5% 75.5% 75.5% -8.3% -8.3% -8.3% -8.3% -23.2% -23.2% -23.24%
Book Value 3Y 91.8% 92.5% 93.7% 95.1% 1.4% 1.4% 1.5% 1.6% 75.8% 82.6% 82.4% 80.5% -4.8% -5.3% -5.9% -6.6% -22.4% -22.6% -22.59%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.75 0.76 0.63 0.69 0.82 0.90 0.84 0.63 0.42 0.31 0.34 0.20 0.12 0.08 0.01 0.00 0.00 0.01 0.02 0.05 0.052
Earnings Stability 0.73 0.74 0.56 0.65 0.80 0.90 0.60 0.39 0.21 0.03 0.02 0.00 0.01 0.01 0.06 0.10 0.17 0.22 0.29 0.35 0.351
Margin Stability 0.86 0.84 0.74 0.69 0.88 0.87 0.73 0.68 0.83 0.68 0.66 0.60 0.67 0.73 0.64 0.56 0.68 0.45 0.40 0.07 0.072
Rev. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.50 0.50 0.50 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 0.00 1.00 1.00 1.000
FCF Positive Streak 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.20 0.20 0.20 0.50 0.50 0.50 0.50 0.50 0.50 0.20 0.20 0.20 0.20 0.50 0.50 0.50 0.50 0.84 0.92 0.98 0.981
Earnings Smoothness 0.00 0.00 0.50 0.63 0.00 0.00
ROE Trend 1.71 3.19 1.23 1.13 0.52 -0.29 0.15 -0.38 -1.12 -1.98 -0.99 -1.07 -0.95 -0.49 -0.38 -0.22 -0.09 -0.11 0.01 0.00 0.000
Gross Margin Trend 0.17 0.10 0.13 0.18 0.04 -0.08 -0.19 -0.23 -0.27 -0.44 -0.47 -0.52 -0.37 0.09 0.03 0.10 0.07 -0.41 -0.29 -0.52 -0.519
FCF Margin Trend 6.05 2.77 3.61 3.90 1.49 -1.45 -1.35 -1.24 -0.96 -0.94 -1.06 -1.03 -0.96 -0.79 -1.11 -0.95 -0.71 -0.66 -0.14 0.29 0.288
Sustainable Growth Rate 1.9% 3.8% 1.5% 1.8% 1.7% 1.4% 50.3% 28.8% 7.3%
Internal Growth Rate 3.6% -2.7% 3.2% 10.7% 7.2% 2.8% 49.5% 23.4% 5.0%
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 2.63 1.64 1.12 0.92 0.69 0.56 0.60 0.21 -0.19 0.60 0.66 0.48 0.55 1.44 0.84 0.91 0.93 0.63 0.66 0.45 0.452
FCF/OCF 0.99 0.98 0.98 0.97 0.95 0.94 0.92 0.62 3.34 1.28 1.23 1.27 1.23 1.23 1.35 1.32 1.30 1.35 1.11 1.09 1.095
FCF/Net Income snapshot only 0.495
CapEx/Revenue 1.6% 1.6% 1.6% 1.7% 2.0% 2.1% 2.1% 2.6% 5.0% 6.3% 10.4% 15.3% 14.7% 14.8% 32.9% 31.3% 26.2% 30.8% 10.4% 6.2% 6.16%
CapEx/Depreciation snapshot only 0.583
Accruals Ratio -1.28 -1.01 -0.09 0.08 0.28 0.32 0.13 0.15 0.06 -0.05 -0.07 -0.14 -0.12 0.04 -0.03 -0.02 -0.01 -0.07 -0.07 -0.13 -0.132
Sloan Accruals snapshot only -0.119
Cash Flow Adequacy snapshot only -10.547
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.02 $0.02 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio 0.2% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF Payout Ratio 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Total Payout Ratio 0.2% 0.1% 7.0% 10.1% 19.8% 32.2% 39.8% 67.6% 2.1%
Div. Increase Streak 0 0
Chowder Number
Buyback Yield 0.0% 0.0% 0.8% 2.0% 4.6% 7.8% 4.6% 5.2% 5.5% 4.0% 2.9% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -0.0% -0.0% 0.7% 1.9% 4.5% 7.6% 4.5% 5.1% 5.4% 3.8% 2.8% 1.4% -0.1% -0.3% -0.4% -0.5% -0.3% -0.3% -0.3% -0.3% -0.25%
Total Shareholder Return -0.0% -0.0% 0.7% 1.9% 4.5% 7.6% 4.5% 5.1% 5.4% 3.8% 2.8% 1.4% -0.1% -0.3% -0.4% -0.5% -0.3% -0.3% -0.3% -0.3% -0.25%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 0.92 0.93 0.92 0.90 0.90 0.88 0.87 0.95 1.48 1.47 1.20 1.24 1.35 0.95 0.99 0.99 0.99 0.99 1.02 1.02 1.018
Interest Burden (EBT/EBIT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.99 0.95 1.02 1.01 1.01 1.01 1.01 1.01 1.01 1.00 1.00 1.00 0.98 0.983
EBIT Margin 0.57 0.67 0.75 0.74 0.70 0.65 0.51 0.34 0.08 -0.25 -0.57 -0.92 -0.86 -0.46 -1.12 -1.08 -0.96 -1.42 -1.42 -1.43 -1.434
Asset Turnover 1.50 2.54 1.11 1.37 1.39 1.29 0.75 0.58 0.42 0.36 0.31 0.23 0.23 0.23 0.20 0.19 0.19 0.14 0.15 0.17 0.168
Equity Multiplier 2.39 2.39 1.92 1.92 1.92 1.92 1.52 1.52 1.52 1.52 1.34 1.34 1.34 1.34 1.32 1.32 1.32 1.32 1.35 1.35 1.354
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $8.11 $16.27 $28.31 $34.36 $33.54 $28.56 $20.65 $11.81 $3.17 $-9.10 $-11.93 $-15.62 $-15.28 $-5.57 $-9.25 $-8.70 $-7.48 $-7.99 $-7.20 $-8.09 $-8.09
Book Value/Share $5.94 $5.90 $32.82 $33.20 $33.76 $34.33 $47.22 $47.22 $50.19 $50.19 $35.07 $36.27 $36.08 $34.72 $28.31 $28.24 $28.10 $27.95 $22.07 $21.90 $18.75
Tangible Book/Share $5.94 $5.90 $32.82 $33.20 $33.76 $34.33 $47.22 $47.22 $50.19 $50.19 $34.83 $36.02 $35.83 $34.48 $28.08 $28.00 $27.86 $27.72 $22.07 $21.90 $21.90
Revenue/Share $15.51 $26.17 $41.15 $51.49 $53.18 $50.18 $46.60 $36.48 $27.69 $24.05 $17.28 $13.49 $13.10 $12.67 $8.31 $8.13 $7.89 $5.69 $4.96 $5.63 $5.63
FCF/Share $21.08 $26.24 $30.94 $30.59 $21.99 $15.05 $11.31 $1.51 $-1.98 $-6.97 $-9.68 $-9.61 $-10.36 $-9.91 $-10.53 $-10.45 $-9.02 $-6.83 $-5.24 $-4.01 $-4.01
OCF/Share $21.32 $26.67 $31.60 $31.48 $23.04 $16.09 $12.30 $2.45 $-0.59 $-5.45 $-7.89 $-7.54 $-8.44 $-8.04 $-7.80 $-7.91 $-6.95 $-5.07 $-4.72 $-3.66 $-3.66
Cash/Share $10.69 $10.62 $24.89 $25.18 $25.60 $26.04 $24.45 $24.45 $25.99 $25.99 $21.78 $22.52 $22.41 $21.56 $18.25 $18.20 $18.11 $18.01 $14.79 $14.68 $13.18
EBITDA/Share $9.13 $17.93 $31.39 $38.87 $38.13 $33.22 $24.55 $13.38 $3.20 $-4.77 $-8.32 $-10.97 $-9.83 $-5.01 $-8.82 $-8.28 $-7.02 $-7.53 $-6.51 $-7.48 $-7.48
Debt/Share $0.55 $0.55 $2.13 $2.15 $2.19 $2.22 $2.96 $2.96 $3.15 $3.15 $3.15 $3.25 $3.24 $3.12 $1.94 $1.94 $1.93 $1.92 $4.89 $4.85 $4.85
Net Debt/Share $-10.14 $-10.07 $-22.76 $-23.03 $-23.42 $-23.81 $-21.49 $-21.49 $-22.84 $-22.84 $-18.64 $-19.27 $-19.17 $-18.45 $-16.31 $-16.26 $-16.18 $-16.10 $-9.91 $-9.83 $-9.83
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 3.854
Altman Z-Prime snapshot only 8.306
Piotroski F-Score 6 6 7 7 7 5 6 5 4 4 4 3 3 3 4 3 3 3 3 1 1
Beneish M-Score 50.38 23.10 7.84 0.81 0.66 1.59 -2.29 -1.88 -1.89 -5.44 -3.62 -0.08 -5.51 -3.42 -2.07 -2.39 -2.23 44.36 -3.84 -2.10 -2.097
Ohlson O-Score snapshot only -7.877
ROIC (Greenblatt) snapshot only -43.06%
Net-Net WC snapshot only $7.23
EVA snapshot only $-3172180000.00
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only BBB
Credit Score 97.04 97.01 96.92 96.90 97.16 97.14 97.45 96.86 90.00 65.04 65.72 65.32 65.62 65.55 61.79 55.35 59.00 54.49 53.13 59.63 59.635
Credit Grade snapshot only 9
Credit Trend snapshot only 4.283
Implied Spread (bps) snapshot only 275.000
Industry Credit Rank snapshot only 55
Sector Credit Rank snapshot only 52

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms